Neogenomics (NEO) Total Non-Current Liabilities (2016 - 2026)
Neogenomics filings provide 15 years of Total Non-Current Liabilities readings, the most recent being $433.2 million for Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities changed 0.07% to $433.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $433.2 million, a 0.07% change, with the full-year FY2025 number at $435.0 million, changed 0.12% from a year prior.
- Total Non-Current Liabilities hit $433.2 million in Q1 2026 for Neogenomics, roughly flat from $435.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $672.5 million in Q1 2022 to a low of $433.2 million in Q1 2026.
- Median Total Non-Current Liabilities over the past 5 years was $637.9 million (2023), compared with a mean of $550.0 million.
- Biggest five-year swings in Total Non-Current Liabilities: increased 15.36% in 2022 and later plummeted 32.47% in 2024.
- Neogenomics' Total Non-Current Liabilities stood at $652.1 million in 2022, then dropped by 1.33% to $643.4 million in 2023, then plummeted by 32.47% to $434.5 million in 2024, then grew by 0.12% to $435.0 million in 2025, then fell by 0.41% to $433.2 million in 2026.
- The last three reported values for Total Non-Current Liabilities were $433.2 million (Q1 2026), $435.0 million (Q4 2025), and $438.6 million (Q3 2025) per Business Quant data.